Matthew P. Blischak - 08 Jun 2023 Form 4 Insider Report for Finch Therapeutics Group, Inc. (FNCH)

Role
Chief Executive Officer
Signature
By: /s/ Matthew P. Blischak
Issuer symbol
FNCH
Transactions as of
08 Jun 2023
Net transactions value
$0
Form type
4
Filing time
09 Jun 2023, 16:52:05 UTC
Previous filing
16 May 2023
Next filing
23 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FNCH Stock Option (right to buy) Award $0 +962,899 $0.000000 962,899 08 Jun 2023 Common Stock 962,899 $0.2850 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option shall vest on June 8, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.